Drug
VX-745 clinical trials
Also written VX-745 and Neflamapimod.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
10 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
EIP Pharma Inc (9) · University Hospital, Toulouse (1)
Studies
Open first, then newest update. How each study uses VX-745 is read from its arms, and is right about nine times in ten.
Testing it · 10
- RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesCompletedPhase 2EIP Pharma IncNCT05869669Written as Neflamapimod
- A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic StrokeActive, not recruitingPhase 2EIP Pharma IncNCT06987643Written as Neflamapimod
- A Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesCompletedPhase 2EIP Pharma IncNCT06815965Written as neflamapimod
- Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaActive, not recruitingPhase 2EIP Pharma IncNCT07033481Written as Neflamapimod
- Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy BodiesCompletedPhase 2EIP Pharma IncNCT04001517Written as Neflamapimod
- Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease PatientsCompletedPhase 2University Hospital, ToulouseNCT03435861Written as VX-745
- Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington DiseaseTerminatedPhase 2EIP Pharma IncNCT03980938Written as neflamapimod
- Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's DiseaseCompletedPhase 2EIP Pharma IncNCT03402659Written as neflamapimod
- A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)CompletedPhase 2EIP Pharma IncNCT02423122Written as VX-745
- Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild ADCompletedPhase 2EIP Pharma IncNCT02423200Written as VX-745
Codes
What other systems call VX-745 · ClinicalTrials.gg INT004474
- MeSH (NLM) C464966VX-745Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) TYL52QM320NEFLAMAPIMODConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C464966 | VX-745 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TYL52QM320 | NEFLAMAPIMOD | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.